[HTML][HTML] Acute respiratory distress syndrome

…, M Herridge, AG Randolph, CS Calfee - Nature reviews Disease …, 2019 - nature.com
The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in
critically ill patients and is defined by the acute onset of noncardiogenic pulmonary oedema, …

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

…, R Pinotti, MD Taylor, P Sinha, CS Calfee… - The Lancet …, 2020 - thelancet.com
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However, direct …

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

CS Calfee, K Delucchi, PE Parsons… - The Lancet …, 2014 - thelancet.com
Background Subphenotypes have been identified within heterogeneous diseases such as
asthma and breast cancer, with important therapeutic implications. We assessed whether …

A living WHO guideline on drugs for covid-19

…, FAJ Barragan, FJ Bausch, E Burhan, CS Calfee… - 2022 - scholar.sun.ac.za
This living guideline by Arnav Agarwal and colleagues (BMJ 2020; 370: m3379, doi: 10.1136/bmj.
m3379) was last updated on 22 April 2022, but the infographic contained two dosing …

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

E Fan, JR Beitler, L Brochard, CS Calfee… - The Lancet …, 2020 - thelancet.com
The COVID-19 pandemic has seen a surge of patients with acute respiratory distress syndrome
(ARDS) in intensive care units across the globe. As experience of managing patients …

Is a “cytokine storm” relevant to COVID-19?

P Sinha, MA Matthay, CS Calfee - JAMA internal medicine, 2020 - jamanetwork.com
In its most severe form, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

…, X Fang, K Cosgrove, R Vojnik, CS Calfee… - The Lancet …, 2015 - thelancet.com
Background No effective pharmacotherapy for acute respiratory distress syndrome (ARDS)
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …

Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy

…, KD Liu, BT Thompson, CS Calfee - American journal of …, 2017 - atsjournals.org
Rationale: We previously identified two acute respiratory distress syndrome (ARDS) subphenotypes
in two separate randomized controlled trials with differential response to positive end…

[HTML][HTML] Redefining critical illness

…, RM Baron, M Bauer, TG Buchman, CS Calfee… - Nature medicine, 2022 - nature.com
Research and practice in critical care medicine have long been defined by syndromes,
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …

A living WHO guideline on drugs for covid-19

…, FAJ Barragan, FJ Bausch, E Burhan, CS Calfee… - bmj, 2020 - bmj.com
Updates This is the thirteenth version (twelfth update) of the living guideline, replacing earlier
versions (available as data supplements). New recommendations will be published as …